Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

OBJECTIVE To determine the cost-effectiveness of three alternative high-quality treatments for attention deficit hyperactivity disorder (ADHD) relative to community care (CC) and to determine whether cost-effectiveness varies with the presence of comorbid disorders. DATA SOURCES/COLLECTION: The study included 579 children ages 7-9.9 with diagnosed ADHD at six sites. Data for the study were distilled from administrative data and from interviews with parents, including estimates of the child's functional impairment. These analyses focus on changes in functional impairment over 14 months. STUDY DESIGN The study involved a large clinical trial that randomized participants to one of four arms: routine CC, intensive medication management (MedMgt), multicomponent behavioral treatment, and a combination of behavioral treatment and medication. PRINCIPAL FINDINGS We assessed the cost-effectiveness of the alternatives using costs measured from a payer perspective. The preferred cost-effective treatment varies as a function of the child's comorbidity and of the policy maker's willingness to pay. For pure (no comorbidity) ADHD, high-quality MedMgt appears likely to be cost-effective at all levels of willingness to pay. In contrast, for some comorbid conditions, willingness to pay is critical: the policy maker with low willingness to pay likely will judge MedMgt most cost-effective. On the other hand, a policy maker willing to pay more now in expectation of future costs savings (involving, for example, juvenile justice), will recognize that the most cost-effective choice for comorbid conditions likely involves behavior therapy, with or without medication. CONCLUSIONS Analyses of costs and effectiveness of treatment for ADHD must consider the role of comorbidities.

[1]  J. Swanson,et al.  Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. , 2005, The American journal of psychiatry.

[2]  D. Pritchard.  Attention deficit hyperactivity disorder in children. , 2005, Clinical evidence.

[3]  C. Koyanagi,et al.  Medicaid policies to contain psychiatric drug costs. , 2005, Health affairs.

[4]  J. Swanson,et al.  The services for children and adolescents-parent interview: development and performance characteristics. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  J. Severe,et al.  Reliability of the services for children and adolescents-parent interview. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  P. Owens,et al.  Multimodal treatment for ADHD among youths in three Medicaid subgroups: disabled, foster care, and low income. , 2004, Psychiatric services.

[7]  E. Howell.  Access to Children's Mental Health Services under Medicaid and SCHIP , 2004 .

[8]  Benedetto Vitiello,et al.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. , 2004, JAMA.

[9]  M. Schlander.  MH3 COST-EFFECTIVENESS OF METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN EVALUATION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS) , 2004 .

[10]  J. Biederman.  Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. , 2004, The Journal of clinical psychiatry.

[11]  T. Wilens.  Impact of ADHD and its treatment on substance abuse in adults. , 2004, The Journal of clinical psychiatry.

[12]  H. Kraemer,et al.  Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. , 2003, Journal of consulting and clinical psychology.

[13]  Elizabeth B. Owens,et al.  Which treatment for whom for ADHD? Moderators of treatment response in the MTA. , 2003, Journal of consulting and clinical psychology.

[14]  C. Koyanagi,et al.  Child & adolescent psychiatry: Accessing Medicaid's child mental health services: the experience of parents in two states. , 2003, Psychiatric services.

[15]  Tom V. Hanley,et al.  Response to Commentary on the Multimodal Treatment Study of ADHD (MTA): Mining the Meaning of the MTA , 2002, Journal of abnormal child psychology.

[16]  A. Briggs,et al.  Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.

[17]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[18]  A H Briggs,et al.  Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.

[19]  R. Milne,et al.  Methylphenidate in children with hyperactivity: review and cost–utility analysis , 2001, Pharmacoepidemiology and drug safety.

[20]  J M Swanson,et al.  Symptom profiles in children with ADHD: effects of comorbidity and gender. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  H. Kraemer,et al.  ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  Elizabeth B. Owens,et al.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[23]  J. Swanson,et al.  Psychosocial Treatment Strategies in the MTA Study: Rationale, Methods, and Critical Issues in Design and Implementation , 2000, Journal of abnormal child psychology.

[24]  N. Zethraeus,et al.  Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.

[25]  Phil A. Silva,et al.  Mental disorders and violence in a total birth cohort: results from the Dunedin Study. , 2000, Archives of general psychiatry.

[26]  M. Gabe.  Mental health: a report of the Surgeon General. , 2000, Home care provider.

[27]  P. Jensen.  Current concepts and controversies in the diagnosis and treatment of attention deficit hyperactivity disorder , 2000, Current psychiatry reports.

[28]  Stephen P. Hinshaw,et al.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. , 1999, Archives of general psychiatry.

[29]  W. Pelham.  The NIMH Multimodal Treatment Study for Attention-Deficit Hyperactivity Disorder: Just Say Yes to Drugs Alone? , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[30]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[31]  R. Scheffler,et al.  Changing Supply and Earning Patterns of the Mental Health Workforce , 1998, Administration and Policy in Mental Health and Mental Health Services Research.

[32]  P. Raina,et al.  Attention deficit hyperactivity disorder in children. Benefits of adding other forms of treatment to medication remain unclear. , 1998, BMJ.

[33]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[34]  J. Swanson,et al.  Comprehensive assessment of childhood Attention-Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial , 1997 .

[35]  G. Canino,et al.  GLOBAL MEASURES OF IMPAIRMENT FOR EPIDEMIOLOGIC AND CLINICAL USE WITH CHILDREN AND ADOLESCENTS , 1996 .

[36]  J. Swanson,et al.  NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[37]  D. Shaffer,et al.  The Columbia Impairment Scale (CIS): Pilot findings on a measure of global impairment for children and adolescents. , 1993 .

[38]  M. Davies,et al.  The Diagnostic Interview Schedule for Children-Revised Version (DISC-R): II. Test-retest reliability. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[39]  M Davies,et al.  The Diagnostic Interview Schedule for Children-Revised Version (DISC-R): I. Preparation, field testing, interrater reliability, and acceptability. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[41]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[42]  D. Clough,et al.  Emergency Services and Disaster Relief Branch Division of Program Development, Special Populations and Projects Center for Mental Health Services Substance Abuse and Mental Health Services Administration , 2008 .

[43]  H. Meltzer,et al.  Service utilisation by children with conduct disorders--findings from the GB National Study. , 2003, European child & adolescent psychiatry.

[44]  R. Manderscheid,et al.  Mental Health, United States, 2000. , 2001 .

[45]  Wendy Richardson.  Criminal behavior fueled by attention deficit hyperactivity disorder and addiction. , 2000 .

[46]  S. Paisley,et al.  The clinical effectiveness and cost effectiveness of methylphenidate for hyperactivity in childhood , 2000 .

[47]  J. Swanson,et al.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. , 1999, Archives of general psychiatry.

[48]  Robert Haveman,et al.  Schooling and Economic Well-Being: The Role of Nonmarket Effects , 1984 .